AGMB (AgomAb Therapeutics NV) Marketable Securities: $35.24 Mil (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Marketable Securities?

AgomAb Therapeutics NV AGMB +0.85% 14 Marketable Securities is $35.24 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. AgomAb Therapeutics NV's Marketable Securities for the quarter that ended in Dec. 2025 was $35.24 Mil.

AgomAb Therapeutics NV's annual Marketable Securities stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($35.24 Mil).

AgomAb Therapeutics NV  (NAS:AGMB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

AgomAb Therapeutics NV Marketable Securities Related Terms

AgomAb Therapeutics NV Marketable Securities Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Marketable Securities Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 42.37 0.00 0.00 35.24

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Marketable Securities Get a 7-Day Free Trial 42.37 0.00 0.00 0.00 35.24
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $35.24 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Marketable Securities of $35.24 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Marketable Securities too high?
AgomAb Therapeutics NV's current Marketable Securities is $35.24 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Marketable Securities compare to DNA and ACRS?
AgomAb Therapeutics NV's Marketable Securities of $35.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Marketable Securities is $35.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Marketable Securities of $35.24 Mil. The current Marketable Securities is $35.24 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Marketable Securities is $35.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price